Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5846939 | 1.00 | CA1 (0.56) | CA1CA2CA4CA7NPSR1 | |
| SCHEMBL5845479 | 1.00 | CA1 (0.56) | CA1CA2CA4CA7NPSR1 | |
| SCHEMBL4460115 | 0.85 | GABRA1 (0.49) | CA1CA2CA4CA7MAPT | |
| SCHEMBL4460122 | 0.85 | GABRA1 (0.49) | CA1CA2CA4CA7MAPT | |
| SCHEMBL21827664 | 0.85 | MAPT (0.52) | CA1CA2CA4CA7NPSR1 | |
| SCHEMBL15714026 | 0.85 | CA1 (0.47) | CA1CA2CA4CA7NPSR1 | |
| SCHEMBL16983620 | 0.85 | CA1 (0.47) | CA1CA2CA4CA7NPSR1 | |
| SCHEMBL21827667 | 0.85 | MAPT (0.52) | CA1CA2CA4CA7NPSR1 | |
| SCHEMBL4755187 | 0.85 | MAPT (0.52) | CA1CA2CA4CA7NPSR1 | |
| SCHEMBL7979263 | 0.84 | CA1 (0.56) | CA1CA2CA4CA7NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010013-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USES IN MANUFACTURE OF A MEDICAMENT FOR TREATMENT AND PREVENTION OF VIRAL DISEASES | BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2010-01-14 | — | — | US | disclosed |
| US-7074784-B2 | Nitrogen compounds such as methyl 4-(2-chloro-4-fluorophenyl) -2-(3,5-difluoropyridin-2-yl)-6-(4-morpholinylmethyl)-1,4-dihydropyrimidine -5-carboxylate, with mixtures of lamivudine and interferons, used as viricides; hepatitis | Goldmann, Siegfried (DE) | 2006-07-11 | — | — | US | disclosed |
| US-20040167135-A1 | Dihydropyrimidines | BAYER AKTIENGESELLSCHAFT (DE) | 2004-08-26 | — | — | US | disclosed |
| EP-1265889-B1 | MEDICAMENTS AGAINST VIRAL DISEASES | BAYER HEALTHCARE AG (DE) | 2004-06-16 | — | — | EP | disclosed |
| US-6696451-B1 | NITROGEN COMPOUND SUCH AS ETHYL-4-(2-BROMOPHENYL)-2-(3-FLUORO PYRIDIN-2-YL)-6-METHYL-1,4-DIHYDROPYRIMIDIN-5-CARBOXYLATE, USED FOR THE PROPHYLAXIS OF VIRAL DISEASES SUCH AS HEPATITIS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-02-24 | — | — | US | disclosed |
| US-20030232842-A1 | Medicaments against viral diseases | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2003-12-18 | — | — | US | disclosed |
| EP-1265889-A1 | MEDICAMENTS AGAINST VIRAL DISEASES | Bayer Aktiengesellschaft (DE) | 2002-12-18 | — | — | EP | disclosed |
| EP-1080086-B1 | DIHYDROPYRIMIDINES | BAYER AG (DE) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001068642-A1 | DIHYDROPYRIMIDINES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001068641-A1 | 6-AMINOALKYL-DIHYDROPYRIMIDINES AND THE USE THEREOF AS MEDICAMENTS AGAINST VIRAL DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001068640-A1 | MEDICAMENTS AGAINST VIRAL DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001068639-A1 | DIHYDROPYRIMIDINE-5-CARBOXYLIC ACID ESTERS AND USE THEREOF AS MEDICAMENTS AGAINST VIRAL DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167135-A1 | Dihydropyrimidines | DPYD, DHFR, DHPS | CA1 2989/4885CA2 3424/4885CA4 2717/4885 |
| US-20030232842-A1 | Medicaments against viral diseases | HAVCR2, ENTPD5, TYMP | CA1 4432/4885CA2 2451/4885CA4 2080/4885 |
| US-20100010013-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USES IN MANUFACTURE OF A MEDICAMENT FOR TREATMENT AND PREVENTION OF VIRAL DISEASES | DPYD, DHFR, HPRT1 | CA1 2745/4885CA2 2406/4885CA4 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.